Experimental gene therapy aims to fix cystinosis at the source

NCT ID NCT03897361

First seen Jun 24, 2026 · Last updated Aug 07, 2026 · Updated 3 times

Summary

This early-phase trial tested a gene therapy for cystinosis, a rare genetic disorder that causes cystine crystals to build up in cells, damaging organs. Researchers took blood stem cells from 6 patients, added a working copy of the faulty gene, and infused the corrected cells back into the patients. The goal was to see if the treatment is safe and can lower cystine levels, potentially reducing the need for daily medication.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
gene-modified stem cells (CTNS-RD-04)
What this could lead to
If successful, this could lead to a one-time treatment that reduces or eliminates the need for daily cystine-lowering medication in people with cystinosis.
What could go wrong
This is a very early, small trial with only 6 participants. The gene therapy may not work for everyone, and there are risks from the stem cell transplant procedure, including possible side effects or complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYSTINOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of California San Diego

    La Jolla, California, 92093, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.